| Shamrock Vna Hha Agency Inc | |
| 60 Katona Drive, Fairfield, Connecticut 6824 | |
| (203) 256-1804 | |
| Name | Shamrock Vna Hha Agency Inc |
|---|---|
| Location | 60 Katona Drive, Fairfield, Connecticut |
| Certified By | Medicare |
| Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
| Medicare ID | 77181 |
| Ownership Type | Proprietary |
| Service Area Zip Codes | 6604, 6605, 6606, 6607, 6608, 6610, 6611, 6612, 6614, 6615, 6824, 6825, 6880, 6890 |
| NPI Number | 1871569707 |
| Organization Name | PATHWELL CT, INC. |
| Doing Business As | SHAMROCK HOME CARE |
| Address | 99 Hawley Ln Ste 1001, Stratford, CT 06614 |
| Phone Number | 203-256-1804 |
News Archive
A limitation of current cancer care is the difficulty of quickly assessing how well a therapy is working. However, expanding the use of existing positron emission tomography (PET) technology can provide early and accurate assessment of a tumor's response to a particular therapy allowing physicians to better tailor a patient's treatment
Ninety-two percent of seniors enrolled in the Medicare Part D prescription drug benefit in 2008 are satisfied with their coverage according to a national phone survey by RetireSafe, a nationwide education and advocacy group for older Americans.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced presentation of results from a preclinical study of its novel oncology drug candidate, M402, in a murine pancreatic cancer model.
Researchers at the University of Minnesota's Stem Cell Institute have described how an existing genetic tool can be used to study how human embryonic stem cells differentiate.
› Verified 8 days ago
| Quality Rating: |
News Archive
A limitation of current cancer care is the difficulty of quickly assessing how well a therapy is working. However, expanding the use of existing positron emission tomography (PET) technology can provide early and accurate assessment of a tumor's response to a particular therapy allowing physicians to better tailor a patient's treatment
Ninety-two percent of seniors enrolled in the Medicare Part D prescription drug benefit in 2008 are satisfied with their coverage according to a national phone survey by RetireSafe, a nationwide education and advocacy group for older Americans.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced presentation of results from a preclinical study of its novel oncology drug candidate, M402, in a murine pancreatic cancer model.
Researchers at the University of Minnesota's Stem Cell Institute have described how an existing genetic tool can be used to study how human embryonic stem cells differentiate.
› Verified 8 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often the home health team began their patients’ care in a timely manner | 95.3 | 95.7 |
| How often the home health team taught patients (or their family caregivers) about their drugs | 99.1 | 98.6 |
| How often the home health team checked patients’ risk of falling | 100 | 99.6 |
| How often the home health team checked patients for depression | 93.5 | 97.4 |
| How often the home health team made sure that their patients have received a flu shot for the current flu season. | 80.2 | 78.7 |
| How often the home health team made sure that their patients have received a pneumococcal vaccine (pneumonia shot). | 93.5 | 82.2 |
| With diabetes, how often the home health team got doctor’s orders, gave foot care, and taught patients about foot care | 97.3 | 96.4 |
News Archive
A limitation of current cancer care is the difficulty of quickly assessing how well a therapy is working. However, expanding the use of existing positron emission tomography (PET) technology can provide early and accurate assessment of a tumor's response to a particular therapy allowing physicians to better tailor a patient's treatment
Ninety-two percent of seniors enrolled in the Medicare Part D prescription drug benefit in 2008 are satisfied with their coverage according to a national phone survey by RetireSafe, a nationwide education and advocacy group for older Americans.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced presentation of results from a preclinical study of its novel oncology drug candidate, M402, in a murine pancreatic cancer model.
Researchers at the University of Minnesota's Stem Cell Institute have described how an existing genetic tool can be used to study how human embryonic stem cells differentiate.
› Verified 8 days ago
| Quality Measure | Provider | National Avg. |
|---|---|---|
| How often patients got better at walking or moving around | 60 | 79.6 |
| How often patients got better at getting in and out of bed | 50.8 | 81.1 |
| How often patients got better at bathing | 52.9 | 82.3 |
| How often patients’ breathing improved | 83.3 | 82.8 |
| How often patients’ wounds improved or healed after an operation | - | 92.3 |
| How often patients got better at taking their drugs correctly by mouth | 50 | 75 |
| How often home health patients had to be admitted to the hospital | 12.2 | 15.4 |
| How often patients receiving home health care needed urgent, unplanned care in the ER without being admitted | 16.9 | 13 |
| How often physician-recommended actions to address medication issues were completely timely | 95.3 | 94 |
News Archive
A limitation of current cancer care is the difficulty of quickly assessing how well a therapy is working. However, expanding the use of existing positron emission tomography (PET) technology can provide early and accurate assessment of a tumor's response to a particular therapy allowing physicians to better tailor a patient's treatment
Ninety-two percent of seniors enrolled in the Medicare Part D prescription drug benefit in 2008 are satisfied with their coverage according to a national phone survey by RetireSafe, a nationwide education and advocacy group for older Americans.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced presentation of results from a preclinical study of its novel oncology drug candidate, M402, in a murine pancreatic cancer model.
Researchers at the University of Minnesota's Stem Cell Institute have described how an existing genetic tool can be used to study how human embryonic stem cells differentiate.
› Verified 8 days ago
| Question Type: | Rating by Patients |
|---|---|
| Health team gave care in a professional way | |
| Health team communicated well with them | |
| Health team discussed medicines, pain, and home safety | |
| How patients rated overall care from agency |
News Archive
A limitation of current cancer care is the difficulty of quickly assessing how well a therapy is working. However, expanding the use of existing positron emission tomography (PET) technology can provide early and accurate assessment of a tumor's response to a particular therapy allowing physicians to better tailor a patient's treatment
Ninety-two percent of seniors enrolled in the Medicare Part D prescription drug benefit in 2008 are satisfied with their coverage according to a national phone survey by RetireSafe, a nationwide education and advocacy group for older Americans.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced presentation of results from a preclinical study of its novel oncology drug candidate, M402, in a murine pancreatic cancer model.
Researchers at the University of Minnesota's Stem Cell Institute have described how an existing genetic tool can be used to study how human embryonic stem cells differentiate.
› Verified 8 days ago
The patient survey data of Shamrock Vna Hha Agency Inc is compared against the national average with the color code indicators: Better than National Average Worse than National Average| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percent of patients who reported that their home health team gave care in a professional way | 87 | 88 |
| Percent of patients who reported that their home health team communicated well with them | 87 | 85 |
| Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 83 | 83 |
| Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 80 | 84 |
| Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 72 | 78 |
News Archive
A limitation of current cancer care is the difficulty of quickly assessing how well a therapy is working. However, expanding the use of existing positron emission tomography (PET) technology can provide early and accurate assessment of a tumor's response to a particular therapy allowing physicians to better tailor a patient's treatment
Ninety-two percent of seniors enrolled in the Medicare Part D prescription drug benefit in 2008 are satisfied with their coverage according to a national phone survey by RetireSafe, a nationwide education and advocacy group for older Americans.
Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced presentation of results from a preclinical study of its novel oncology drug candidate, M402, in a murine pancreatic cancer model.
Researchers at the University of Minnesota's Stem Cell Institute have described how an existing genetic tool can be used to study how human embryonic stem cells differentiate.
› Verified 8 days ago
Shamrock Vna Hha Agency Inc Location: 60 Katona Drive, Fairfield, Connecticut 6824 Ratings: Phone: (203) 256-1804 | |
Interim Healthcare Of Fairfield County Location: 1817 Black Rock Tnpk, Suite 102, Fairfield, Connecticut 6825 Ratings: NA Phone: (203) 309-0606 |